Are you fairly interested in the field of cancer research? Have you experienced cancer on a first-hand basis? Do you know someone who has suffered with this disease? Cancer has been around for centuries, and it has been unleashing a wave of devastation along its path. Millions of people have succumb to this illness throughout the years, but progression in cancer research has stepped-up its game. Seattle Genetics is at the apex of the industry thanks to being able to evolve with the times. This phenomenal company was started back in the late 1990s by Dr. Clay Siegall. In its early days, Seattle Genetics struggled mightily as it was spending more than it was actually earning. Dr. Siegall, and his small team of professionals had to honker-down or the company would eventually fold.
By implementing a superior sales staff, Seattle Genetics would begin to pull itself from a hole. The staff would eventually become the face of the business as it routinely closed on seven-figure deals. In some cases, the company was able to close on eight-figure deals. Human antibodies and Seattle Genetics goes hand-to-hand. Dr. Siegall’s knowledge on the subject is unsurpassed as he has brought-forth drug development, rigorous research and scientific innovation. Prior to the company finding its footing, it wasn’t earning too much capital because it wasn’t retaining any of its patents. In other words, the medications that were being produced by this company was actually owned by another company.
As of today, Dr. Siegall has learned from his mistakes. He is the current holder of at least 15 patents, and he is looking to push the company’s boundaries via international marketing. All in all, the future of Seattle Genetics is in great hands thanks to Dr. Clay Siegall because he’s setting new industry standards, and he’s changing the status quo.